What is the problem with Bayer Trasylol (Bayer aprotinin)?
Bayer Trasylol was approved by the FDA and sold worldwide for the last 13 years and
has been administered to an estimated one million patients. Bayer Trasylol now proves
to double a patient's risk of kidney failure, and increase the risk of Trasylol
heart attack, heart failure, stroke, and encephalopathy brain disease during coronary artery bypass surgery. Thus there are now efforts to move forward with a Trasylol class action lawsuit and invididual claims.
The problem with Bayer Trasylol is that the lack of drug
safety is not only too common but perhaps misrepresented by multi-billion dollar
pharmaceutical companies who may be more concerned about investor relations than
patients' health. (Read More)
Personal Injury Disclaimer: This website provides general information about Pennsylvania Trasylol lawsuits and other legal information. Nothing on this site is intended to be legal advice. The materials on this site may be considered advertising. Nothing on this site constitutes the formation of an attorney client relationship. This website is not intended to solicit clients outside the Commonwealth of Pennsylvania. In order to discuss representation, we must personally speak with you and enter into a signed, written agreement for representation. By utilizing this site, you agree to the foregoing.